Intec Pharma gets $750,000 grant for Parkison’s research

Intec Pharma has developed a new delivery method for Levodopa, the leading treatment for Parkison's disease.

By GALI WEINREB
brain research center 370 (photo credit: Hebrew University)
brain research center 370
(photo credit: Hebrew University)
Intec Pharma Ltd. has obtained a $750,000 grant from the Michael J Fox Foundation for Parkinson’s research. Intec Pharma has developed a new delivery method for Levodopa, the leading treatment for the disease.
Levodopa is effective but does not last long in the bloodstream, and it must therefore be given in large doses, resulting in side effects. Intec Pharma’s accordion capsule releases the drug gradually, extending its effectiveness and lowering the dosage. The company successfully conducted a phase-2 clinical trial of the drug and is seeking a partner to commercialize it.
The Michael J Fox Foundation makes grants of up to $1 million a year. Two other Israeli companies have previously received grants: Neuroderm Ltd., which has received two grants; and Proneuron Biotechnologies, which has gone out of business.
Intec Pharma’s share price fell 0.4 percent to NIS 1.36 on Sunday, giving it a market cap of NIS 292m.